Alvotech closed at $4.86 on Nov 6, up 6.81%, 21.0% below its 52-week closing high. Volume of 1.0M shares was 1.20× its 20-day average (close to normal).
Split-adjusted performance: -14.3% over one month, +49.1% over six months, -0.4% over one year.
Short interest was 6.4M shares at the Oct 15 settlement (5.5% of float, 5.7 days to cover).
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
What is ALVO's market cap?
$1.73B, based on the Nov 6 close of $4.86.
Does Alvotech pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ALVO is sold short?
6.4M shares, 5.5% of float, as of Oct 15, 2026.
About Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
